CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...

A decade of studies from labs around the world provide a growing evidence base that increasing the power of the brain's gamma rhythms could help fight Alzheimer's, and perhaps other, neurological ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...

According to the terms of the deal, Blackstone will acquire a 60 percent stake while CMIC HD will retain the remaining 40 percent stake in the company.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC ...

Patrick Tan’s project in Singapore will create Asia’s first functional precision medicine system with the potential to fine-tune treatments and drug responses for Asians.